208 related articles for article (PubMed ID: 16034466)
1. PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation.
Murati A; Gelsi-Boyer V; Adélaïde J; Perot C; Talmant P; Giraudier S; Lodé L; Letessier A; Delaval B; Brunel V; Imbert M; Garand R; Xerri L; Birnbaum D; Mozziconacci MJ; Chaffanet M
Leukemia; 2005 Sep; 19(9):1692-6. PubMed ID: 16034466
[No Abstract] [Full Text] [Related]
2. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2.
Reiter A; Walz C; Watmore A; Schoch C; Blau I; Schlegelberger B; Berger U; Telford N; Aruliah S; Yin JA; Vanstraelen D; Barker HF; Taylor PC; O'Driscoll A; Benedetti F; Rudolph C; Kolb HJ; Hochhaus A; Hehlmann R; Chase A; Cross NC
Cancer Res; 2005 Apr; 65(7):2662-7. PubMed ID: 15805263
[TBL] [Abstract][Full Text] [Related]
3. Myeloproliferative disorders carrying the t(8;9) (PCM1-JAK2) translocation.
Bousquet M; Brousset P
Hum Pathol; 2006 Apr; 37(4):500; author reply 500-2. PubMed ID: 16564930
[No Abstract] [Full Text] [Related]
4. The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene.
Bousquet M; Quelen C; De Mas V; Duchayne E; Roquefeuil B; Delsol G; Laurent G; Dastugue N; Brousset P
Oncogene; 2005 Nov; 24(48):7248-52. PubMed ID: 16091753
[TBL] [Abstract][Full Text] [Related]
5. JAK the trigger.
Mahon FX
Oncogene; 2005 Nov; 24(48):7125-6. PubMed ID: 16007127
[TBL] [Abstract][Full Text] [Related]
6. A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma.
Adélaïde J; Pérot C; Gelsi-Boyer V; Pautas C; Murati A; Copie-Bergman C; Imbert M; Chaffanet M; Birnbaum D; Mozziconacci MJ
Leukemia; 2006 Mar; 20(3):536-7. PubMed ID: 16424865
[No Abstract] [Full Text] [Related]
7. Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1.
Patterer V; Schnittger S; Kern W; Haferlach T; Haferlach C
Ann Hematol; 2013 Jun; 92(6):759-69. PubMed ID: 23400675
[TBL] [Abstract][Full Text] [Related]
8. Myelodysplastic/myeloproliferative disease with erythropoietic hyperplasia (erythroid preleukemia) and the unique translocation (8;9)(p23;p24): first description of a case.
Heiss S; Erdel M; Gunsilius E; Nachbaur D; Tzankov A
Hum Pathol; 2005 Oct; 36(10):1148-51. PubMed ID: 16226118
[TBL] [Abstract][Full Text] [Related]
9. A t(8;9)(p22;p24)/PCM1-JAK2 translocation in a patient with myeloproliferative neoplasm and myeloid sarcoma: first report in Korea.
Song I; Lee DH; Lee JH; Jang S; Huh JR; Seo EJ
Ann Lab Med; 2016 Jan; 36(1):79-81. PubMed ID: 26522767
[No Abstract] [Full Text] [Related]
10. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia.
Griesinger F; Hennig H; Hillmer F; Podleschny M; Steffens R; Pies A; Wörmann B; Haase D; Bohlander SK
Genes Chromosomes Cancer; 2005 Nov; 44(3):329-33. PubMed ID: 16001431
[TBL] [Abstract][Full Text] [Related]
11. JAK2 V617F mutation in leukaemic transformation of philadelphia-negative chronic myeloproliferative disorders.
Rossi D; Deambrogi C; Capello D; Cerri M; Lunghi M; Parvis G; Saglio G; Gaidano G; Cilloni D
Br J Haematol; 2006 Oct; 135(2):267-8. PubMed ID: 16956348
[No Abstract] [Full Text] [Related]
12. Extramedullary T-lymphoid blast crisis of an ETV6/ABL1-positive myeloproliferative neoplasm with t(9;12)(q34;p13) and t(7;14)(p13;q11.2).
Yamamoto K; Yakushijin K; Nakamachi Y; Miyata Y; Sanada Y; Tanaka Y; Okamura A; Kawano S; Hayashi Y; Matsuoka H; Minami H
Ann Hematol; 2014 Aug; 93(8):1435-8. PubMed ID: 24318592
[No Abstract] [Full Text] [Related]
13. Two alternatively spliced 5'BCR/3'JAK2 fusion transcripts in a myeloproliferative neoplasm with a three-way t(9;18;22)(p23;p11.3;q11.2) translocation.
Impera L; Lonoce A; Fanfulla DA; Moreilhon C; Legros L; Raynaud S; Storlazzi CT
Cancer Genet; 2011 Sep; 204(9):512-5. PubMed ID: 22018274
[TBL] [Abstract][Full Text] [Related]
14. Pathology of the bone marrow and spleen in a case of myelodysplastic/myeloproliferative neoplasm associated with t(8;9)(p22;p24) involving PCM1 and JAK2 genes.
Dargent JL; Mathieux V; Vidrequin S; Deghorain X; Vannuffel P; Rack K
Eur J Haematol; 2011 Jan; 86(1):87-90. PubMed ID: 21070368
[No Abstract] [Full Text] [Related]
15. Implication of MAPK1/MAPK3 signalling pathway in t(8;9)(p22;24)/PCM1-JAK2 myelodysplastic/myeloproliferative neoplasms.
Masselli E; Mecucci C; Gobbi G; Carubbi C; Pierini V; Sammarelli G; Bonomini S; Prezioso L; Rossetti E; Caramatti C; Aversa F; Vitale M
Br J Haematol; 2013 Aug; 162(4):563-6. PubMed ID: 23701125
[No Abstract] [Full Text] [Related]
16. Mutations of N-RAS, FLT3 and p53 genes are not involved in the development of acute leukemia transformed from myeloproliferative diseases with JAK2 mutation.
Suzuki M; Abe A; Kiyoi H; Murata M; Ito Y; Shimada K; Morishita Y; Kinoshita T; Naoe T
Leukemia; 2006 Jun; 20(6):1168-9. PubMed ID: 16557239
[No Abstract] [Full Text] [Related]
17. A myeloproliferative neoplasm with translocation t(8;9)(p22;p24) involving JAK2 gene.
Saba N; Safah H
Blood; 2013 Aug; 122(6):861. PubMed ID: 24079014
[No Abstract] [Full Text] [Related]
18. The V617F JAK2 mutation and the myeloproliferative disorders.
Percy MJ; McMullin MF
Hematol Oncol; 2005; 23(3-4):91-3. PubMed ID: 16285006
[TBL] [Abstract][Full Text] [Related]
19. JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
Quentmeier H; MacLeod RA; Zaborski M; Drexler HG
Leukemia; 2006 Mar; 20(3):471-6. PubMed ID: 16408098
[TBL] [Abstract][Full Text] [Related]
20. JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients.
Vizmanos JL; Ormazábal C; Larráyoz MJ; Cross NC; Calasanz MJ
Leukemia; 2006 Mar; 20(3):534-5. PubMed ID: 16408096
[No Abstract] [Full Text] [Related]
[Next] [New Search]
